104 related articles for article (PubMed ID: 1683626)
21. The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia.
Meltzer HY; Sommers AA; Luchins DJ
J Clin Psychopharmacol; 1986 Dec; 6(6):329-38. PubMed ID: 2879856
[TBL] [Abstract][Full Text] [Related]
22. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
[TBL] [Abstract][Full Text] [Related]
23. [Use of low doses of bromocriptine in chronic schizophrenia resistant to neuroleptics. A preliminary study].
Wolf MA; Diener JM; Lajeunesse C; Shriqui C
J Psychiatry Neurosci; 1992 Jun; 17(2):68-71. PubMed ID: 1637801
[TBL] [Abstract][Full Text] [Related]
24. Effect of anticholinergics on positive and negative symptoms in schizophrenia.
Tandon R; DeQuardo JR; Goodson J; Mann NA; Greden JF
Psychopharmacol Bull; 1992; 28(3):297-302. PubMed ID: 1480733
[TBL] [Abstract][Full Text] [Related]
25. Suspension of neuroleptic therapy in acute schizophrenia.
Kuhs H; Eikelmann B
Pharmacopsychiatry; 1988 Jul; 21(4):197-202. PubMed ID: 2905064
[TBL] [Abstract][Full Text] [Related]
26. Methylphenidate challenge as a predictor of relapse in schizophrenia.
Lieberman JA; Kane JM; Gadaleta D; Brenner R; Lesser MS; Kinon B
Am J Psychiatry; 1984 May; 141(5):633-8. PubMed ID: 6143506
[TBL] [Abstract][Full Text] [Related]
27. [Evaluation trial on the efficacy of neuroleptics on the outcome of schizophrenia].
Dollfus S; Petit M
Encephale; 1991; 17(4):247-53. PubMed ID: 1683625
[TBL] [Abstract][Full Text] [Related]
28. Neuroleptic responsivity of negative and positive symptoms in schizophrenia.
Breier A; Wolkowitz OM; Doran AR; Roy A; Boronow J; Hommer DW; Pickar D
Am J Psychiatry; 1987 Dec; 144(12):1549-55. PubMed ID: 3688278
[TBL] [Abstract][Full Text] [Related]
29. Effect of antipsychotic withdrawal on negative symptoms in schizophrenia.
Miller DD; Flaum M; Arndt S; Fleming F; Andreasen NC
Neuropsychopharmacology; 1994 Aug; 11(1):11-20. PubMed ID: 7945739
[TBL] [Abstract][Full Text] [Related]
30. Clinical predictors of relapse following neuroleptic withdrawal.
Buchanan RW; Kirkpatrick B; Summerfelt A; Hanlon TE; Levine J; Carpenter WT
Biol Psychiatry; 1992 Jul; 32(1):72-8. PubMed ID: 1356490
[TBL] [Abstract][Full Text] [Related]
31. Initial improvement as predictor of outcome of neuroleptic treatment.
Nedopil N; Rüther E
Pharmacopsychiatria; 1981 Nov; 14(6):205-7. PubMed ID: 6119712
[TBL] [Abstract][Full Text] [Related]
32. Effects of neuroleptic reduction in schizophrenic outpatients receiving high doses.
Leblanc G; Cormier H; Gagné MA; Vaillancourt S
Can J Psychiatry; 1994 May; 39(4):223-9. PubMed ID: 7913872
[TBL] [Abstract][Full Text] [Related]
33. Drug withdrawal in chronic schizophrenic patients: in search of neuroleptic-induced supersensitivity psychosis.
Weinberger DR; Bigelow LB; Klein ST; Wyatt RJ
J Clin Psychopharmacol; 1981 May; 1(3):120-3. PubMed ID: 6117582
[TBL] [Abstract][Full Text] [Related]
34. Attentional dysfunctions in neuroleptic-naive and neuroleptic-withdrawn schizophrenic patients and their siblings.
Finkelstein JR; Cannon TD; Gur RE; Gur RC; Moberg P
J Abnorm Psychol; 1997 May; 106(2):203-12. PubMed ID: 9131840
[TBL] [Abstract][Full Text] [Related]
35. [Acute schizophrenia concept and definition: investigation of a French psychiatrist population].
Baylé FJ; Misdrahi D; Llorca PM; Lançon C; Olivier V; Quintin P; Azorin JM
Encephale; 2005; 31(1 Pt 1):10-7. PubMed ID: 15971635
[TBL] [Abstract][Full Text] [Related]
36. Age of illness onset and schizophrenic symptomatology during an inpatient washout period.
Sharma RP; Dowd SM; Davis JM; Janicak PG
Schizophr Res; 1996 Jul; 20(3):295-300. PubMed ID: 8827856
[TBL] [Abstract][Full Text] [Related]
37. Changes in psychopathology and dyskinesia after neuroleptic withdrawal in a double-blind design.
Dixon L; Thaker G; Conley R; Ross D; Cascella N; Tamminga C
Schizophr Res; 1993 Oct; 10(3):267-71. PubMed ID: 8260445
[TBL] [Abstract][Full Text] [Related]
38. Electroencephalographic sleep in clinically stable schizophrenic patients: two-weeks versus six-weeks neuroleptic-free.
Nofzinger EA; van Kammen DP; Gilbertson MW; Gurklis JA; Peters JL
Biol Psychiatry; 1993 Jun 1-15; 33(11-12):829-35. PubMed ID: 8104041
[TBL] [Abstract][Full Text] [Related]
39. Time course of antipsychotic effects of neuroleptic drugs.
Keck PE; Cohen BM; Baldessarini RJ; McElroy SL
Am J Psychiatry; 1989 Oct; 146(10):1289-92. PubMed ID: 2571305
[TBL] [Abstract][Full Text] [Related]
40. Including children and adolescents with schizophrenia in medication-free research.
Kumra S; Briguglio C; Lenane M; Goldhar L; Bedwell J; Venuchekov J; Jacobsen LK; Rapoport JL
Am J Psychiatry; 1999 Jul; 156(7):1065-8. PubMed ID: 10401453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
